Cytokinetics to Participate in November Investor Conferences

Rhea-AI Summary

Cytokinetics (Nasdaq: CYTK) said members of its management team will participate in two investor conferences in November 2025: a Stifel 2025 Healthcare Conference fireside chat on Tuesday, November 11, 2025 at 11:20 AM ET in New York, and a Jefferies Global Healthcare Conference fireside chat on Monday, November 17, 2025 at 2:30 PM GMT in London.

Interested parties can access live webcasts via the Investors & Media section of the Cytokinetics website. Webcast replays will be archived on the site for 90 days after each event.

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in November:

• Stifel 2025 Healthcare Conference: Fireside chat on Tuesday, November 11, 2025 at 11:20 AM Eastern Time in New York, NY.
• Jefferies Global Healthcare Conference: Fireside chat on Monday, November 17, 2025 at 2:30 PM Greenwich Mean Time in London, England.
  
  

Interested parties may access the live webcasts of the fireside chats by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replays will be archived on the Cytokinetics website for 90 days following the conclusion of the event.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), ulacamten, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Disclaimer
Aficamten, omecamtiv mecarbil, ulacamten and CK-089 are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

FAQ

When will Cytokinetics (CYTK) present at the Stifel 2025 Healthcare Conference?

Cytokinetics will present on Tuesday, November 11, 2025 at 11:20 AM ET in New York.

What time is Cytokinetics (CYTK) scheduled at the Jefferies Global Healthcare Conference?

The Cytokinetics fireside chat is on Monday, November 17, 2025 at 2:30 PM GMT in London.

How can investors watch the Cytokinetics (CYTK) conference webcasts live?

Live webcasts are available on the Investors & Media section of the Cytokinetics website.

Will Cytokinetics (CYTK) archive the conference replays and for how long?

Yes. Webcast replays will be archived on the Cytokinetics website for 90 days following each event.

Are the Cytokinetics (CYTK) conference events open to the public online?

Yes. Interested parties may access the live webcasts online via the Cytokinetics investor site.

Which executives from Cytokinetics (CYTK) will appear at the November 2025 fireside chats?

The announcement says members of the company management team will participate; specific individuals were not listed.